Abstract
Ever since the FDA-approval of the combined immune checkpoint (ICP) inhibition with the programmed death 1 (PD-1) antibody Nivolumab and the cytotoxic T-lymphocyte antigen 4 (CTLA4) antibody Ipilimumab for the treatment of malignant melanoma, the range and our understanding of immune-related adverse events (irAE) keeps broadening. Algorithms for the management of common irAE events such as colitis or thyroiditis have been established. However, monitoring and treatment for less common adverse events (AE) can be challenging. We present the case of a 54-year-old male melanoma patient who developed severe thrombocytopenia (CTCAE grade 4) due to combined ICP inhibition and was successfully re-challenged with ICP monotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the European Academy of Dermatology and Venereology : JEADV
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
